The Serum Institute of India is set to bolster the distribution of its human papillomavirus (HPV) vaccine, aiming to provide doses to the government at reduced rates for an immunization campaign targeting the cancer-causing virus. Adar Poonawalla, CEO of the world's largest vaccine manufacturer in terms of doses produced, anticipates the vaccine's inclusion in the government's program by the year's end.

Currently priced at 2,000 rupees ($24.13) in the private market, the indigenous HPV vaccine represents India's maiden endeavor against the virus, which contributes to a significant portion of global cervical cancer cases. Poonawalla emphasized the soaring demand for the vaccine, stating that their current capacity, though limited to a few million doses, falls short of meeting the extensive demand. The government plans to administer the HPV vaccine to girls aged nine to 14, as part of the campaign to combat cervical cancer, the second-most prevalent cancer among Indian women.

While no formal contract has been established with the government, Poonawalla anticipates an initial procurement of 40 to 50 million doses through a tender process in December. Despite competition from other HPV vaccine manufacturers like Merck & Co and GSK Plc, Serum Institute remains steadfast in its commitment to providing an affordable and accessible solution. Poonawalla foresees a significant reduction in vaccine costs, estimated to be around eight times cheaper, when supplied to the government.